SFDA Unveils Five-Year Plan To Raise Drug Supervision Standards
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA aims to raise drug quality and supervision standards over the next five years to reach international levels and to control risks associated with traditional Chinese medicines, according to Wu Zhen, deputy director of SFDA